The Phase 1 trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of CT-868 in overweight or obese but otherwise healthy volunteers and patients with type 2 diabetes.
This Phase 1 study is a randomised, double-blind, placebo-controlled, dose escalation trial in overweight or obese healthy volunteers and patients with type 2 diabetes.
The first phase of the study will evaluate CT-868 in single ascending doses. The second phase of the study will consist of multiple ascending doses over 14 days.
The third phase will evaluate repeat dosing of CT-868 in patients with type 2 diabetes over a 28-day period and will include additional assessments of body weight and body fat composition.
Carmot Therapeutics is a biotechnology company dedicated to the discovery and development of innovative medicines.
Carmot applies a transformative and patented drug discovery approach, Chemotype Evolution, to overcome major limitations in existing discovery methods, providing Carmot a unique opportunity to tackle challenging disease targets and identify superior therapeutics.
The company is applying Chemotype Evolution internally and in collaboration with industry partners such as Amgen and Genentech.
Carmot has identified drug leads targeting class-B GPCRs, protein-protein interactions, and deubiquitinating enzymes and is advancing a portfolio of wholly-owned programmes in metabolic disease and oncology.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes